Your fact-checks will appear here
Organization
No explicit, formal endorsements or dedicated recommendations for repurposed antiparasitic drugs appear in the recent guideline summaries and updates from the National Comprehensive Cancer Network (NC...
Drug–drug interactions and P‑glycoprotein (P‑gp) considerations have been raised in reviews of ivermectin’s repositioning for cancer, but available clinical evidence in cancer patients is sparse and m...
Available sources show Dr. Pete Sulack promotes holistic, “functional/metabolic” and repurposed-drug protocols, supplements and faith-based therapies and has many public testimonials and media appeara...
High-dose ivermectin has been proposed as an oncology adjunct but human data on safety at those doses are limited; clinical reports and reviews warn of central nervous system (CNS) toxicity (blurred v...
Major oncology guideline bodies (NCCN, ESMO, ASCO) have not adopted ivermectin as a recommended cancer treatment; available sources report only early-phase trials and preclinical work, with one active...
Current expert guidance recommends next‑generation molecular PET—preferably PSMA‑PET—plus pelvic MRI when evaluating suspected recurrence before offering curative‑intent salvage radiation therapy; gui...
The Cancer Moonshot began under the Obama administration in 2016 with $1.8 billion in supplemental funding authorized by the 21st Century Cures Act and an initial $300 million first installment (Beau ...
Federal budget actions in 2025 have led to large, rapid reductions in NIH/NCI funding and related programs that press experts warn will hit specific cancer research activities hard: Democratic staff a...